Related Experiment Videos
[Overactive bladder: modulating the effects of antimuscarinic therapy]
G Palleschi1, A Tubaro, L Miano
1Unità Operativa Complessa di Urologia, Azienda Ospedaliera Sant'Andrea, Seconda Facoltà di Medicina e Chirurgia Università degli Studi di Roma La Sapienza, Roma, Italy. giovannipalleschi@libero.it
Summary
Overactive bladder (OAB) affects millions globally. New extended-release tolterodine improves OAB treatment tolerability and efficacy, with nighttime dosing further reducing side effects.
Area of Science:
- Urology
- Pharmacology
- Gerontology
Context:
- Overactive bladder (OAB) is a widespread condition impacting millions across all age groups.
- OAB significantly diminishes quality of life and incurs substantial socio-economic costs.
- Epidemiological data has spurred research interest and the development of diagnostic tools like voiding diaries.
Purpose:
- To explore advancements in Overactive bladder (OAB) diagnosis and treatment.
- To evaluate the efficacy and tolerability of new therapeutic strategies for OAB.
- To highlight improved drug formulations and administration for better patient outcomes.
Summary:
- Antimuscarinics are common OAB treatments, but side effects like dry mouth and constipation limit their use.
- Pharmacological research focuses on developing drugs with enhanced selectivity, organ specificity, and novel delivery systems.
- Extended-release tolterodine demonstrates improved tolerability while maintaining efficacy for OAB management.
Impact:
- New diagnostic tools aid in the earlier and easier identification of OAB.
- Extended-release tolterodine offers a better tolerability profile compared to conventional formulations.
- Night-time administration of tolterodine may further reduce adverse effects, enhancing patient adherence and therapeutic outcomes.